Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 2/20 | 0.40 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17439187 | 1.00 | ALDH1A1 (0.45) | ALDH1A1CA2CA1SMN1; SMN2KDM4E | |
| SCHEMBL20951937 | 1.00 | ALDH1A1 (0.45) | ALDH1A1CA2CA1SMN1; SMN2KDM4E | |
| SCHEMBL232440 | 1.00 | ALDH1A1 (0.45) | ALDH1A1CA2CA1SMN1; SMN2KDM4E | |
| SCHEMBL6026642 | 1.00 | ALDH1A1 (0.45) | ALDH1A1CA2CA1SMN1; SMN2KDM4E | |
| SCHEMBL359087 | 1.00 | ALDH1A1 (0.45) | ALDH1A1CA2CA1SMN1; SMN2KDM4E | |
| SCHEMBL23896338 | 1.00 | ALDH1A1 (0.45) | ALDH1A1CA2CA1SMN1; SMN2KDM4E | |
| SCHEMBL6026636 | 1.00 | ALDH1A1 (0.45) | ALDH1A1CA2CA1SMN1; SMN2KDM4E | |
| Benzene SCHEMBL3449157 | 0.95 | MME (0.45) | ALDH1A1CA2CA1SMN1; SMN2KDM4E | |
| Glycine SCHEMBL20898378 | 0.88 | ALDH1A1 (0.41) | ALDH1A1CA2CA1SMN1; SMN2KDM4E | |
| SCHEMBL30953203 | 0.88 | MME (0.41) | ALDH1A1CA2CA1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 836 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-26 | — | — | US | claimed |
| US-12584101-B2 | Compositions and method of use for H5 competent Bifidobacterium longum subsp. Infantis | INFINANT HEALTH, INC. (US) | 2026-03-24 | — | — | US | claimed |
| US-20250388855-A1 | COMPOSITIONS AND METHOD OF USE FOR H5 COMPETENT BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS | Infinant Health, Inc (US) | 2025-12-25 | — | — | US | claimed |
| EP-4583917-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2025-07-16 | — | — | EP | claimed |
| CN-119923279-A | Prostate Specific Membrane Antigen (PSMA) ligands and uses thereof | 3B制药有限公司 | 2025-05-02 | — | — | CN | claimed |
| EP-3555615-B9 | MASS SPECTROMETRY ASSAY METHOD FOR DETECTION AND QUANTITATION OF KIDNEY FUNCTION METABOLITES | METABOLON INC (US) | 2025-03-19 | — | — | EP | claimed |
| WO-2024230246-A1 | POLYPEPTIDE RADIONUCLIDE COMPLEX TARGETING FIBROBLAST ACTIVATION PROTEIN AND USE THEREOF | 成都纽瑞特医疗科技股份有限公司 | 2024-11-14 | — | — | WO | claimed |
| EP-3555615-B1 | MASS SPECTROMETRY ASSAY METHOD FOR DETECTION AND QUANTITATION OF KIDNEY FUNCTION METABOLITES | METABOLON INC (US) | 2024-10-30 | — | — | EP | claimed |
| US-12076432-B2 | Method of repairing oxidatively treated hair | CONOPCO, INC. (US) | 2024-09-03 | — | — | US | claimed |
| US-20240271083-A1 | COMPOSITIONS AND METHOD OF USE FOR H5 COMPETENT BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS | INFINANT HEALTH, INC. (US) | 2024-08-15 | — | — | US | claimed |
| US-6524593-B1 | Alleviate or improve various cosmetic conditions and dermatological disorders, skin, hair, nails | TRISTRATA, INC. | 2003-02-25 | — | — | US | claimed |
| EP-1077692-A1 | AMINO ACID STABILIZED GABAPENTIN AND PREGABALIN PREPARATIONS AND PROCESS FOR PREPARING THE SAME | Warner-Lambert Company LLC (US) | 2001-02-28 | — | — | EP | claimed |
| US-6159485-A | COSMETICS; SKIN DISORDERS | YUGENIC LIMITED PARTNERSHIP (US) | 2000-12-12 | — | — | US | claimed |
| WO-2000040217-B1 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | YUGENIC LIMITED PARTNERSHIP (US) | 2000-10-05 | — | — | WO | claimed |
| WO-1999059573-A1 | STABILIZED PHARMACEUTICAL PREPARATIONS OF GAMMA-AMINOBUTYRIC ACID DERIVATIVES AND PROCESS FOR PREPARING THE SAME | WARNER-LAMBERT COMPANY (US) | 1999-11-25 | — | — | WO | claimed |
| WO-1998053795-B1 | COSMETIC AND DERMOPHARMACEUTICAL COMPOSITIONS CONTAINING THREONINE OR SERINE DERIVATIVES | — | 1999-02-11 | — | — | WO | claimed |
| WO-1998053795-A1 | COSMETIC AND DERMOPHARMACEUTICAL COMPOSITIONS CONTAINING THREONINE OR SERINE DERIVATIVES | SEDERMA S.A. (FR) | 1998-12-03 | — | — | WO | claimed |
| US-5519000-A | OLIGOPEPTIDE | CENTECOR, INC. (US) | 1996-05-21 | — | — | US | claimed |
| WO-1995026744-A1 | TUMOR NECROSIS FACTOR INHIBITORS | CENTOCOR, INC. (US) | 1995-10-12 | — | — | WO | claimed |
| US-5008372-A | Reacting with anhydrous trifluoroacetic acid | CORNELL RESEARCH FOUNDATION, INC. (US) | 1991-04-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | KLK3, FOLH1, PSMA1 | ALDH1A1 1372/4885CA2 109/4885CA1 10/4885 |
| US-12584101-B2 | Compositions and method of use for H5 competent Bifidobacterium longum subsp. Infantis | FUT5, VNN1, FUT8 | ALDH1A1 3094/4885CA2 3993/4885CA1 2740/4885 |
| US-20250388855-A1 | COMPOSITIONS AND METHOD OF USE FOR H5 COMPETENT BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS | MRPL21, VNN1, NT5M | ALDH1A1 3766/4885CA2 4792/4885CA1 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.